NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

January 24, 2020

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

January 22, 2020

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

January 17, 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

January 16, 2020

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

January 16, 2020

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

January 16, 2020

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

January 08, 2020

We traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer, which featured insights from the NYU Langone’s Perlmutter Cancer Center faculty.

November 27, 2019

Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.

November 23, 2019

Jeffrey S. Weber, MD, PhD, discusses the phase III EORTC1325/KEYNOTE-054 trial, which looked at adjuvant pembrolizumab in patients with stage III melanoma.

November 20, 2019

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.

November 09, 2019

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

November 07, 2019

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

October 25, 2019

Jeffrey S. Weber, MD, PhD, discusses the future of checkpoint inhibitors in melanoma.

October 21, 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

October 18, 2019

Jeffrey S. Weber, MD, PhD, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

October 08, 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

October 02, 2019

Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.

September 19, 2019

Sylvia Adams, MD, discusses the biology of triple-negative breast cancer, data sparking excitement in the field, and intriguing trials on the horizon.

September 10, 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

September 10, 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.